CytomX Therapeutics Inc  

(Public, NASDAQ:CTMX)   Watch this stock  
Find more results for CTMX
17.79
+0.37 (2.12%)
Mar 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 17.40 - 18.48
52 week 9.10 - 20.02
Open 17.50
Vol / Avg. 303,598.00/314,972.00
Mkt cap 664.37M
P/E     -
Div/yield     -
EPS -1.63
Shares 36.57M
Beta     -
Inst. own 77%

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -223.74% -391.54%
Operating margin -226.88% -396.10%
EBITD margin - -384.58%
Return on average assets -28.72% -29.72%
Return on average equity -67.05% -57.59%
Employees 78 -
CDP Score - -

Address

151 Oyster Point Blvd Ste 400
SOUTH SAN FRANCISCO, CA 94080-1910
United States - Map
+1-650-5153185 (Phone)
+1-650-3510353 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets. A Probody therapeutic consists of three components produced as a single protein by standard antibody production methodology: an active anti-cancer antibody, a mask for the antibody and a protease-cleavable linker. Its Probody product candidate, CX-072, is directed against programmed death-ligand 1 (PD-L1). CX-072 is based on a monoclonal antibody targeting PD-L1. Its product candidate, CX-2009, is directed against the target CD-166. It is developing a programmed cell death protein 1 (PD-1) Probody therapeutic as an additional approach to block the PD-L1/PD-1 pathway. It is also conducting Integrin alpha-3 PDC program.

Officers and directors

Hoyoung Huh Ph.D. Chairman of the Board
Age: 46
Bio & Compensation  - Reuters
Sean A McCarthy Ph.D. President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Robert C. Goeltz II Chief Financial Officer
Age: 42
Bio & Compensation  - Reuters
Cynthia Jane Ladd Senior Vice President, General Counsel
Age: 60
Bio & Compensation  - Reuters
W. Michael Kavanaugh M.D. Chief Scientific Officer and Head - Research and Non-Clinical Development
Age: 59
Bio & Compensation  - Reuters
Rachel W. Humphrey M.D. Chief Medical Officer
Age: 54
Bio & Compensation  - Reuters
John A. Scarlett M.D. Director
Age: 65
Bio & Compensation  - Reuters
Neil Exter Independent Director
Bio & Compensation  - Reuters
Frederick Gluck Independent Director
Age: 80
Bio & Compensation  - Reuters
Timothy M. Shannon M.D. Independent Director
Age: 57
Bio & Compensation  - Reuters